Bexion Pharmaceuticals Showcases Key Research at ASCO 2026
Bexion Pharmaceuticals, Inc. is making great strides in the field of oncology with its innovative drug candidate, BXQ-350. This clinical-stage biopharmaceutical company is dedicated to developing effective therapies aimed at treating solid tumor cancers and alleviating chemotherapy-induced peripheral neuropathy (CIPN). As part of this commitment, Bexion is participating in the prestigious American Society for Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026, which will take place over several days. This event is a crucial platform for researchers and healthcare professionals in the cancer field.
Groundbreaking Findings from BXQ-350 Studies
At the upcoming ASCO symposium, Bexion will present several poster sessions detailing the latest findings from their studies involving BXQ-350. This first-in-class therapeutic agent has undergone significant clinical trials examining its safety and efficacy among patients diagnosed with metastatic colorectal carcinoma (mCRC). Each presented study sheds light on the potential benefits of BXQ-350 in managing challenging cancers.
First Poster Highlights
The first poster features an abstract titled "BXQ-350 efficacy and safety evaluation in first-line mCRC patients: A phase 1b/2 study of BXQ-350, a first-in-class sphingolipid metabolism modulator, in combination with mFOLFOX7 plus bevacizumab in newly diagnosed metastatic colorectal carcinoma." This study, led by Dr. Reema Patel, will be presented in Poster Session C dedicated to colon, rectum, and anus cancers. It aims to provide insights into how BXQ-350 performs alongside standard treatment protocols.
Second Poster Presentation Details
The second poster elaborates on a similar efficacy and safety analysis of BXQ-350 in conjunction with mFOLFOX7 and bevacizumab for patients diagnosed with metastatic colorectal carcinoma. Presented by Dr. Tariq Arshad, this trial represents a significant step in understanding the therapeutic landscape for patients undergoing treatment for these types of cancers.
Additional Research and Insights
Bexion's third poster will discuss the effect of BXQ-350 on oxaliplatin-induced CIPN. This study evaluates the efficacy and safety of BXQ-350 in patients treated with FOLFOX7 and aims to uncover strategies to alleviate discomfort from chemotherapy. Michael Gazda, Ph.D., will present these findings, focusing on how BXQ-350 may provide significant relief to patients experiencing CIPN.
The Significance of BXQ-350
Bexion's lead product, BXQ-350, offers a novel therapeutic alternative that combines a multifunctional sphingolipid activator protein with phospholipids. Multiple Phase 1 trials have highlighted a robust safety profile for the drug, demonstrating efficacy across various solid tumors. With potential applications beyond oncology, including relief from CIPN, BXQ-350 represents an innovative shift in cancer therapy and patient care.
About Bexion Pharmaceuticals
Bexion Pharmaceuticals stands at the forefront of biotherapeutic development as it embarks on creating a new generation of treatments aimed at solid tumor cancers and CIPN. The company is exploring broader applications in other cancer types and neuropathic pain indications. With successful enrollment in its Phase 1b/2 study evaluating BXQ-350, Bexion is poised to make meaningful contributions to patient care and outcomes as it continues its clinical trials.
Investor Relations and Media Contact Information
Bexion Pharmaceuticals encourages further inquiries from investors and media representatives. Joyce LaViscount is available for contact and can provide additional information about the company's ongoing projects and strategic objectives.
Frequently Asked Questions
What is BXQ-350?
BXQ-350 is a first-in-class biologic therapy developed by Bexion Pharmaceuticals for treating solid tumors and chemotherapy-induced peripheral neuropathy.
When will Bexion present its research?
Bexion will present its research at the ASCO Gastrointestinal Cancers Symposium, taking place from January 8-10, 2026.
Who will present the findings?
Dr. Reema Patel, Dr. Tariq Arshad, and Michael Gazda, Ph.D., will lead the presentations on the efficacy and safety of BXQ-350.
What are the main objectives of the poster presentations?
The objectives are to showcase the efficacy, safety, and potential benefits of BXQ-350 in treating metastatic colorectal carcinoma and CIPN.
How can I contact Bexion Pharmaceuticals for more information?
You can reach out to Joyce LaViscount for inquiries regarding investor relations or media requests.
